Fate Therapeutics (FATE) Fundamental Analysis: Revenue, Earnings & Valuation

1.11 / 10

Underperform

Fundamental analysis rates FATE as Underperform, scoring 1.1/10. Asset efficiency ratios are modest, but revenue fell 51% YoY and tax-to-profit, receivables, and turnover metrics are poor. Overall financial health appears subpar and challenging.

Analysis Checks(4/10)

Revenue-MV

Value-2.80

Score1/3

Weight40.78%

1M Return5.06%

Total operating revenue (YoY growth rate %)

Value-51.24

Score1/3

Weight-9.37%

1M Return-1.40%

Inventory turnover ratio

Value106.57

Score3/3

Weight-4.37%

1M Return-0.67%

Accounts receivable turnover ratio

Value2.98

Score1/3

Weight-10.88%

1M Return-1.57%

PB-ROE

Value-0.71

Score1/3

Weight40.80%

1M Return5.22%

Income tax / Total profit (%)

Value22.35

Score0/3

Weight-9.83%

1M Return-1.54%

Fixed assets turnover ratio

Value0.06

Score2/3

Weight-6.90%

1M Return-1.01%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.91

Score2/3

Weight-4.88%

1M Return-0.73%

Cost of sales ratio (%)

Value57.03

Score2/3

Weight-4.79%

1M Return-0.74%

Asset-MV

Value-0.55

Score1/3

Weight69.45%

1M Return7.28%

Is FATE undervalued or overvalued?

FATE scores 1.11/10 on fundamentals and holds a Premium valuation at present. Backed by its -51.84% ROE, -2051.08% net margin, -1.05 P/E ratio, 0.69 P/B ratio, and 29.88% earnings growth, these metrics solidify its Underperform investment rating.